2018 AANS Annual Scientific Meeting-641. In Silico Identification of Neo-Antigens in a High-Grade Pediatric Brain Tumor Cohort Utilizing Next-Generation Sequencing: Pilot Study of a Discovery Pipeline for Immunotherapy Targets

641. In Silico Identification of Neo-Antigens in a High-Grade Pediatric Brain Tumor Cohort Utilizing Next-Generation Sequencing: Pilot Study of a Discovery Pipeline for Immunotherapy Targets

Back to course

Video Transcription

Video Summary

In this video, Dr. Peter Mattson discusses his work on identifying neo-antigens in high-grade pediatric brain tumors using next-generation sequencing. He explains that neo-antigens are novel proteins present in tumor cells that make attractive targets for immunotherapies. Using whole genome sequencing and algorithms, Dr. Mattson's team predicts neo-antigens that can be used for personalized vaccines, adoptive immunotherapies, and predicting response to immunotherapies. They specifically focus on pediatric brain tumors due to their poor prognosis and lack of effective therapies. The study found a sufficient number of neo-antigens in the tumors, including shared neo-antigens among different tumor types. Dr. Mattson concludes by discussing future directions for refining the pipeline and designing clinical trials based on this information.

Asset Caption

Peter Madsen, MD

Keywords

Dr. Peter Mattson

neo-antigens

high-grade pediatric brain tumors

next-generation sequencing

immunotherapies